Skip to main content
Hunan Hansen Pharmaceutical Co.,Ltd. logo

Hunan Hansen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Listed
Ticker · 002412 ISIN · CNE100000PK2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,327 across all filing types
Latest filing 2026-06-08 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 002412 · 1 venue

About Hunan Hansen Pharmaceutical Co.,Ltd.

https://www.hansenzy.com

Hunan Hansen Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio encompasses a diverse range of chemical drugs and traditional Chinese medicine (TCM) preparations. Key therapeutic areas include cardiovascular health, digestive system disorders, and anti-infective treatments. Notable products include Simotang Oral Liquid, a widely recognized TCM for gastrointestinal motility, and various chemical formulations such as Simvastatin tablets. The company operates modern production facilities compliant with Good Manufacturing Practice (GMP) standards and maintains a robust R&D infrastructure focused on drug innovation and formulation optimization. Its operations integrate traditional medicinal knowledge with contemporary pharmacological technology to serve healthcare markets through a comprehensive supply chain and clinical research initiatives.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement by Hunan Hansoh Pharmaceutical Co., Ltd. regarding the 2025 annual profit distribution (cash dividend) scheme, including dividend amount per share, total dividend, record date, ex‐dividend date, payment method, and related operational details. This matches the definition of a “Notice of Dividend Amount” (Code: DIV). It is not simply a report publication announcement or a full financial report, but a specific dividend distribution notice.
2026-06-08 Chinese
关于参股公司减少注册资本暨关联交易的公告
Share Issue/Capital Change Classification · 85% confidence The document is an official corporate announcement (“公告”) by Hunan Hansen Pharmaceutical Co., Ltd. detailing a related‐party transaction involving a reduction in registered capital of an associate company. It outlines the capital reduction mechanics, approvals, and impacts on shareholding structure. This fits the “Share Issue/Capital Change” category (SHA) which covers announcements of capital structure changes such as share issues, splits, or reductions.
2026-06-02 Chinese
第七届董事会第二次会议决议的公告
Board/Management Information Classification · 90% confidence The document is an announcement of the resolutions of the company’s 7th Board of Directors 2nd meeting, detailing meeting procedures, votes, and agenda items. This falls squarely under Board/Management Information, since it reports board decisions and related governance matters. There is no financial report content or regulatory filing attachment. Hence, it is classified as MANG.
2026-06-02 Chinese
关于董事会完成换届选举及聘任高级管理人员、财务总监、董事会秘书、内部审计负责人、证券事务代表的公告
Board/Management Information Classification · 92% confidence The document is an official corporate announcement detailing the completion of the board re-election and the appointment of senior management (including board members, finance director, board secretary, internal audit head, and securities affairs representatives). It does not contain financial statements or earnings figures but rather personnel changes at the board and management level. This corresponds to the Board/Management Information category.
2026-05-26 Chinese
湖南启元律师事务所关于湖南汉森制药股份有限公司2025 年度股东会的法律意见书
Regulatory Filings Classification · 86% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, voting procedures, and results of the 2025 annual shareholders’ meeting. It does not itself constitute the company’s formal voting results announcement, nor is it a proxy statement, AGM presentation, or any financial report. Instead, it is a compliance/legal filing (an opinion on the validity of the AGM). Such third-party legal opinions are best classified under the general regulatory/filing category. Therefore, the correct classification is Regulatory Filings (RNS).
2026-05-19 Chinese
关于选举职工代表董事的公告
Board/Management Information Classification · 98% confidence The document is an official announcement from the company’s board regarding the election of an employee representative director, i.e., a change in the board of directors. This fits the Board/Management Information category.
2026-05-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.